Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Erasca ( (ERAS) ) has provided an update.
On January 20, 2026, Erasca, Inc. reported that its preliminary, unaudited cash, cash equivalents and marketable securities totaled approximately $341.8 million as of December 31, 2025, and on January 23, 2026, the company closed an upsized public offering of 25,875,000 common shares, generating estimated net proceeds of $242.7 million. Based on these preliminary figures and management estimates, Erasca now expects to have sufficient liquidity to fund its operations into the first half of 2029, extending its financial runway and potentially strengthening its position to execute its development plans, though the figures remain subject to completion of year-end closing procedures and audit.
The most recent analyst rating on (ERAS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Erasca stock, see the ERAS Stock Forecast page.
Spark’s Take on ERAS Stock
According to Spark, TipRanks’ AI Analyst, ERAS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large losses, and substantial cash burn). Offsetting factors include strong recent technical strength and constructive corporate updates, including pipeline progress and a financing that improves liquidity, though dilution and overextended momentum indicators add risk.
To see Spark’s full report on ERAS stock, click here.
More about Erasca
Erasca, Inc. is a biopharmaceutical company focused on developing therapeutics, with operations that require substantial cash resources to fund ongoing and future development activities.
Average Trading Volume: 4,551,613
Technical Sentiment Signal: Buy
Current Market Cap: $3.25B
See more insights into ERAS stock on TipRanks’ Stock Analysis page.